Holen Sie sich die Stockscreener-App
19.15
1.79%
-0.35
Schlusskurs vom Vortag:
$19.50
Offen:
$19.5
24-Stunden-Volumen:
374.98K
Relative Volume:
0.61
Marktkapitalisierung:
$543.87M
Einnahmen:
$320.35M
Nettoeinkommen (Verlust:
$-75.01M
KGV:
-7.9948
EPS:
-2.3953
Netto-Cashflow:
$-113.17M
1W Leistung:
+5.57%
1M Leistung:
+28.52%
6M Leistung:
-31.09%
1J Leistung:
-8.02%
1-Tages-Spanne:
$18.65
$19.50
1-Wochen-Bereich:
$17.62
$19.93
52-Wochen-Spanne:
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Firmenname
Fulgent Genetics Inc
Sektor
Branche
Telefon
626-350-0537
Adresse
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
19.15 | 553.81M | 320.35M | -75.01M | -113.17M | -2.3953 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Hochstufung | UBS | Neutral → Buy |
| 2023-12-07 | Eingeleitet | UBS | Neutral |
| 2022-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-11-18 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Underperform |
| 2021-01-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2020-11-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-08-20 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-29 | Eingeleitet | BTIG Research | Buy |
| 2019-11-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-03-01 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Fulgent Genetics Inc Aktie (FLGT) Neueste Nachrichten
How The Fulgent Genetics (FLGT) Investment Story Is Evolving With Recent Developments - Yahoo Finance
How Fulgent Genetics Inc. (FLGT) Affects Rotational Strategy Timing - Stock Traders Daily
Fulgent Genetics CSO Gao Hanlin sells $30,190 in stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) insider sale covers RSU taxes - Stock Titan
Fulgent Genetics (FLGT) CFO reports tax withholding of vested RSU shares - Stock Titan
Fulgent Genetics (FLGT) CSO sells 1,688 shares to cover RSU tax - Stock Titan
Fulgent (NASDAQ: FLGT) CEO RSU vest triggers 4,392-share tax withholding - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) Form 144 lists 45,304 vested shares; small prior sale - Stock Titan
Fulgent Presents Updated Phase 2 FID-007 + Cetuximab Data at ASCO Showing 61.9% ORR - TradingView
Fulgent Genetics (FLGT) Presents Promising Data on Head and Neck Cancer Treatment - GuruFocus
Strong FID-007 Phase 2 results for Fulgent Genetics (NASDAQ: FLGT) - Stock Titan
Fulgent Presents Updated FID-007 Data at ASCO 2026 - The Joplin Globe
Fulgent Genetics COO Jian Xie sells $21,137 in company stock By Investing.com - Investing.com Australia
Fulgent Genetics COO Jian Xie sells $21,137 in company stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding - Stock Titan
[Form 4] Fulgent Genetics, Inc. Insider Trading Activity - Stock Titan
Fulgent Genetics (FLGT) CSO sells 945 shares to cover tax obligations - Stock Titan
Ming Hsieh (FLGT) reports 32% Fulgent Genetics stake and major share pledges - Stock Titan
Fulgent Genetics (FLGT) CEO reports RSU tax withholding and large trust holdings - Stock Titan
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87 - MSN
(FLGT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Law firm investigates Fulgent Genetics for possible securities law violations after revenue miss. - Pluang
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent Genetics Presents Promising Phase 2 FID-007 & Cetuximab Data for Head and Neck Cancer at ASCO 2026 - Minichart
Fulgent reports interim data for cancer drug FID-007 trial By Investing.com - Investing.com Australia
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting - BioSpace
Fulgent reports interim data for cancer drug FID-007 trial - Investing.com
Fulgent Announces ASCO Rapid Oral Abstract Showing 60% ORR, 7.2‑mo mPFS for FID-007 plus Cetuximab - TradingView
Fulgent (NASDAQ: FLGT) reports 60% ORR in Phase 2 FID-007 cancer trial - Stock Titan
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
Fulgent Genetics targets wider engagement at APG2026 San Diego exhibit fair - Traders Union
FLGT Stock Chart | FULGENT GENETICS INC (NASDAQ:FLGT) - ChartMill
Fulgent Genetics (FLGT) director receives stock units and 8,426-share option grant - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) director receives 11,117 RSUs - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) director awarded 11,117 restricted stock units - Stock Titan
Fulgent Genetics Shareholders Approve New 2026 Equity Plan - TipRanks
Fulgent Genetics (NASDAQ: FLGT) wins stockholder approval for 2026 equity plan - Stock Titan
ETFs Investing in Fulgent Genetics, Inc. Stocks - TradingView
Responsive Playbooks and the FLGT Inflection - Stock Traders Daily
Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males - Traders Union
TradingKey - TradingKey
LA500 2026: Ming Hsieh - Los Angeles Business Journal
Fulgent Genetics (NASDAQ:FLGT) Stock Passes Below Fifty Day Moving AverageHere's Why - MarketBeat
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Finanzdaten der Fulgent Genetics Inc-Aktie (FLGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):